Noble Romans (NROM) EBITDA (2010 - 2026)

Noble Romans' EBITDA history runs 16 years deep, the most recent figure standing at $550483.0 for Q1 2026.

• On a quarterly basis, EBITDA rose 9.74% year-over-year to $550483.0 in Q1 2026; TTM through Mar 2026 was $2.5 million, a 58.91% increase from a year earlier, with the FY2025 full-year figure at $2.4 million, up 63.08% from the prior year.
• EBITDA improved to $550483.0 in Q1 2026 per NROM's latest filing, from $170788.0 in the prior quarter.
• Across five years, EBITDA topped out at $1.5 million in Q1 2023 and bottomed at -$395.0 in Q4 2022.
• The 5-year median for EBITDA is $501639.0 (2025), against an average of $511346.4.
• Across the five-year window, EBITDA tumbled 272.64% in 2022 and soared 176208.61% in 2023, its largest moves.
• Year by year, EBITDA stood at -$395.0 in 2022, then surged by 176208.61% to $695629.0 in 2023, then plunged by 90.18% to $68282.0 in 2024, then jumped by 150.12% to $170788.0 in 2025, then jumped by 222.32% to $550483.0 in 2026.
• Per Business Quant, the three latest NROM EBITDA figures stand at $550483.0 (Q1 2026), $170788.0 (Q4 2025), and $819065.0 (Q3 2025).